GlassScriptPhysician profile
Mario S Bangco
NPI 1447229141
$4,232.96
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $814 · 2021: $704 · 2022: $742 · 2023: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $431.02 | 2019-2023 | |
| Ucb, INC. | $372.86 | 2019-2023 | Briviact |
| Sunovion Pharmaceuticals INC. | $307.56 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $302.86 | 2019-2023 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $252.88 | 2019-2021 | |
| Emd Serono, INC. | $214.15 | 2019-2022 | |
| Genzyme Corporation | $206.76 | 2019-2022 | |
| Genentech USA, INC. | $203.88 | 2019-2022 | |
| Amgen INC. | $174.14 | 2019-2022 | |
| Abbvie INC. | $166.59 | 2021-2023 | Ubrelvy |
| Supernus Pharmaceuticals, INC. | $142.25 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $132.55 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $103.27 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.10 | 2022 | |
| Neurocrine Biosciences, INC. | $95.43 | 2019-2023 | Ingrezza, Ongentys |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Bangco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.